.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, using up the leading science spot at Sanofi.Quigley will certainly begin Sept. 30 as the French Big Pharma's primary medical officer and global head of research study, Sanofi told Fierce Biotech in an emailed statement.Quigley is actually substituting Frank Nestle, M.D., that left behind Sanofi this springtime amid a global overhaul of the firm's R&D system. Nestle, that invested eight years with the pharma, jumped over to Deerfield Control, where he presently functions as a partner on the therapeutics staff as well as chief executive officer of the organization's healing revelation and growth functions.
Quigley will sign up with Sanofi coming from a San Francisco-based biotech that remains in stealth, depending on to his LinkedIn account. He is actually currently noted as the provider's co-founder, head of state as well as CEO.Because August 2021, Quigley has served as an endeavor companion at SV Health Investors, a medical care fund manager with existing investments in biotechs like BioAge, Cerevance, Dualitas Therapies and Nimbus Therapies, and many more. Quigley formerly held the top area at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The future Sanofi leader also recently helmed Therini Bio, an immunotherapy biotech operating to cultivate therapies for neurodegenerative conditions steered by vascular dysfunction.Before spending the final few years in biotech, Quigley has an also longer performance history in Huge Pharma, most lately functioning as Gilead's elderly vice president of analysis the field of biology up until the summer months of 2021. Before that, he clocked in more than 4 years throughout different leadership functions at Bristol Myers Squibb and served as a medical director at Johnson & Johnson's Janssen upper arm before that.Sanofi mentioned Quigley's mission in his new duty would be actually to "optimize our likelihood of results with superior cooperations throughout our association as well as beyond, taking best-in-class advancement along with creating and also sourcing brand-new industry-leading ability with a devotion to diversity," depending on to an interior memo obtained by STAT.